GPR155 and gastric cancer: Similarly, in patients with Stage II/III GC with or without hematogenous recurrence with significant differences in GPR155 mRNA levels, there were no significant differences in overall survival (Fig. 4B) and disease-free survival (Fig. 4C) between the low and high GPR155 groups.